What generation of drug is Vebreltinib? Introduction to drug generations

Vebreltinib/vebreltinib belongs to the third generation of MET tyrosine kinase inhibitors, which are characterized by stronger inhibitory capabilities against drug resistance and multiple mutant MET signaling pathways. The development of MET-targeted drugs has undergone gradual optimization from the first to the third generation. The first generation of MET inhibitors are mostly non-selective small molecules that can inhibit a variety of kinases, but are not specific enough for MET, have limited efficacy and have many toxic and side effects. The second-generation MET inhibitors have improved selectivity and oral bioavailability, and have shown better control rates for some patients with MET mutations, but they still have problems with drug resistance and insufficient blood-brain barrier penetration.

Bricitinib, as a third-generation drug, has been optimized in structural design forATP binding site, which not only improves the binding ability to MET amplification and exon 14 skipping mutations, but also shows advantages in blood-brain barrier penetration and drug resistance overcoming. This enables it to achieve effective efficacy in brain glioma and MET amplification-related non-small cell lung cancer (NSCLC), and provides a potential treatment option for EGFR-TKI-resistant patients.

Third generationThe clinical significance of MET inhibitors lies not only in improving the efficacy of single drugs, but also in their combined use with other treatment modalities. For example, in the context of failure of chemoradiotherapy or immunotherapy, boricitinib can be used as a targeted treatment option to improve disease control rates while reducing the risk of non-specific toxicity through precise medication. The evolution of generations reflects the strategic optimization of targeted drug development, that is, from broad-spectrum inhibition to high selectivity, from single indication to multi-tumor type application.

In short, as a third-generationMET inhibitor, boricitinib has high selectivity, drug resistance overcoming ability and blood-brain barrier penetration properties. Its generation positioning is clear, providing a new precision treatment plan for patients with MET-abnormal tumors and providing a reference for the optimized development of targeted drugs in the future.

Reference materials:https://www.asymbio.com.cn/